[Treatment by plasmapheresis of a thrombotic thrombocytopenic purpura associated to a Still's disease: a case report].
We report the seventh published case of thrombotic thrombocytopenic purpura (TTP) associated to a Still's disease. We confirmed the secondary character of TTP using the measurement of ADAMTS 13 protease. Because of clinical and biological improvement, daily plasmapheresis was stopped after eight days of ICU treatment. Unfortunately, early (24 hours) relapse occurred resulting in daily plasmapheresis resumption for 11 more days. Main therapeutic goals and aggressive treatment duration of PTT associated with a Still's disease remain to be determined.
Robert
V
V
Service de Réanimation Polyvalente, Hôpital ND-de-Bonsecours, CHR de Metz-Thionville, 1, place Philippe-de-Vigneulles, BP 81065, 57038 Metz cedex 01, France.
Eszto
P
P
Perrotez
J-L
JL
Galzin
M
M
Poussel
J-F
JF
D051722:ADAM Proteins / Q000032:analysis; D000071120:ADAMTS13 Protein; D058186:Acute Kidney Injury / Q000209:etiology; D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology / Q000628:therapy*; D012008:Recurrence; D012640:Seizures / Q000188:drug therapy / Q000209:etiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human